PubMed
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023
Compare
Retatrutide vs VIP
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
Retatrutide
125 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 99% · Mixed 1% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
222
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
3
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 1–2 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
5
0.1–0.2 mg
3
0.2–0.4 mg
6
0.4–0.6 mg
10
0.6–1 mg
5
1–2 mg
80
2–3 mg
35
3–5 mg
17
5+ mg
61
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.
Overall, repeat reporters leaned similar or mixed compared to their previous entry.
Median gap between entries: 51 days · Based on 45 repeat reporters
VIP
25 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 2% · Mixed 2% · Unfavorable overall 96%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
163
Energy
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
83
Headache
77
Self-reported dose per injection
Median bucket: 50–100 mcg · Most common: 50–100 mcg
Reports span 50–200 mcg
50–100
116
100–200
47
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 152 days · Based on 24 repeat reporters
Sources (15)
Published sources linked on the Retatrutide and VIP wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frias JP, et al. N Engl J Med. 2023
- Wiki study page →Source
ClinicalTrials.gov
Retatrutide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
ClinicalTrials.gov
Retatrutide studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. The New England journal of medicine. 2023
- Wiki study page →Source
PubMed
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Katsi V, Koutsopoulos G, Fragoulis C, et al. Biomolecules. 2025
- Wiki study page →Source
PubMed
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
Ghatei MA, Takahashi K, Suzuki H, et al. J Cardiovasc Pharmacol. 2003
- Wiki study page →Source
PubMed
Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo
Delgado M, Chorny A, Gonzalez-Rey E, et al. J Leukoc Biol. 2005
- Wiki study page →Source
PubMed
Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions
Delgado M, Ganea D. Amino Acids. 2013
- Wiki study page →Source
PubMed
Vasoactive intestinal peptide: cardiovascular effects
Henning RJ, Sawmiller DR. Cardiovascular Research. 2001
- Wiki study page →Source
PubMed
Vasoactive intestinal peptide and the mammalian circadian system
Vosko AM, Schroeder A, Loh DH, et al. General and Comparative Endocrinology. 2007
- Wiki study page →Source
PubMed
New perspectives on vasoactive intestinal polypeptide as a widespread modulator of social behavior
Kingsbury MA. Current Opinion in Behavioral Sciences. 2015
- Wiki study page →Source
ClinicalTrials.gov
Vasoactive Intestinal Peptide studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
The significance of vasoactive intestinal peptide in immunomodulation
Delgado M, Pozo D, Ganea D. Pharmacological reviews. 2004
- Wiki study page →Source
PubMed
Role of vasoactive intestinal peptide in osteoarthritis
Jiang W, Wang H, Li YS, et al. Journal of biomedical science. 2016